Table 1.

Population distribution and average percentage of overall joint range-of-motion limitation by hemophilia severity across levels of risk factors studied among 4343 young males with hemophilia who participated in UDC, May 1998-May 2002



Mild, n = 917

Moderate, n = 1048

Severe, n = 2378
Characteristics
No.
%
% Limitation
P*
No.
%
% Limitation
P*
No.
%
% Limitation
P*
Age, y             
   2 to 5   158   17.2   –0.5   <.001   211   20.1   –0.3   <.001   491   20.6   –0.5   <.001  
   6 to 10   259   28.2   –0.3    316   30.2   0.3    711   29.9   0.6   
   11 to 15   312   34.0   0.5    317   30.2   1.4    700   29.4   3.1   
   16 to 19   188   20.5   0.6    204   19.5   3.0    476   20.2   5.9   
Race/ethnicity             
   White, non-Hispanic   631   68.8   0.1   NS   708   67.6   0.8   .01   1492   62.7   1.7   <.001  
   Other   286   31.2   0.3    340   32.4   1.6    886   37.3   2.9   
Hemophilia type             
   A   743   81.0   0.1   NS   737   70.3   1.2   .02   2022   85.0   2.2   NS  
   B   174   19.0   0.2    311   29.7   0.6    356   15.0   1.7   
Family history             
   Yes   754   82.2   0.1   NS   773   73.8   0.9   NS   1367   57.5   2.1   NS  
   No   163   17.8   0.1    275   26.2   1.3    1011   42.5   2.2   
Age at diagnosis             
   At/before birth   370   40.4   –0.1   NS   665   63.4   1.0   NS   2039   85.7   2.0   NS  
   After birth   524   57.1   0.2    354   33.8   1.0    272   11.4   2.6   
Age at first HTC visit, y             
   Younger than 1   255   27.8   –0.1   .02   480   45.8   0.9   NS   1554   65.4   1.7   <.001  
   1 to 2   130   14.2   –0.3    182   17.4   1.0    332   14.0   2.6   
   2+   501   54.6   0.4    339   32.4   1.2    387   16.3   3.2   
Insurance status             
   Insured   884   96.4   0.1   NS   1018   97.1   1.0   NS   2330   98.0   2.1   .03  
   Uninsured   33   3.6   0.1    30   2.9   1.2    48   2.0   3.8   
HTC use             
   Frequent   705   76.9   0.3   .01   924   88.2   1.2   <.01   2248   94.5   2.1   <.01  
   Infrequent   212   23.1   –0.3    124   11.8   0.1    130   5.5   3.4   
Inhibitor status             
   Yes   6   0.6   0   NS   25   2.4   1.5   NS   186   7.8   4.8   <.001  
   No   911   99.4   0.1    1023   97.6   1.0    2192   92.2   1.9   
Prophylaxis use             
   Yes   8   0.9   –0.5   NS   159   15.2   1.6   .04   1056   44.4   1.3   <.001  
   No   909   99.1   0.1    889   84.8   0.9    1322   55.6   2.8   
Body mass index             
   13.0 to 17.0   271   29.6   –0.6   <.001   328   31.3   –0.1   <.001   816   34.3   0.4   <.001  
   17.1 to 21.1   319   34.8   –0.2    352   33.6   0.6    742   31.2   2.1   
   21.2 to 42.0   309   33.7   0.9    345   32.9   2.4    760   32.0   4.1   
No. of bleeds, 6 mo             
   0   408   44.5   0.2   NS   261   24.9   0.6   NS   426   17.9   0.8   <.001  
   1 to 4   432   47.1   0.1    463   44.2   1.0    843   35.4   1.4   
   5+   77   8.4   0.1    322   30.7   1.4    1105   46.5   3.3   
Orthopedic procedure             
   Yes   10   1.1   0.6   NS   17   1.6   2.8   NS   103   4.3   5.6   <.001  
   No
 
907
 
98.9
 
0.1
 

 
1031
 
98.4
 
1.0
 

 
2275
 
95.7
 
2.0
 

 


Mild, n = 917

Moderate, n = 1048

Severe, n = 2378
Characteristics
No.
%
% Limitation
P*
No.
%
% Limitation
P*
No.
%
% Limitation
P*
Age, y             
   2 to 5   158   17.2   –0.5   <.001   211   20.1   –0.3   <.001   491   20.6   –0.5   <.001  
   6 to 10   259   28.2   –0.3    316   30.2   0.3    711   29.9   0.6   
   11 to 15   312   34.0   0.5    317   30.2   1.4    700   29.4   3.1   
   16 to 19   188   20.5   0.6    204   19.5   3.0    476   20.2   5.9   
Race/ethnicity             
   White, non-Hispanic   631   68.8   0.1   NS   708   67.6   0.8   .01   1492   62.7   1.7   <.001  
   Other   286   31.2   0.3    340   32.4   1.6    886   37.3   2.9   
Hemophilia type             
   A   743   81.0   0.1   NS   737   70.3   1.2   .02   2022   85.0   2.2   NS  
   B   174   19.0   0.2    311   29.7   0.6    356   15.0   1.7   
Family history             
   Yes   754   82.2   0.1   NS   773   73.8   0.9   NS   1367   57.5   2.1   NS  
   No   163   17.8   0.1    275   26.2   1.3    1011   42.5   2.2   
Age at diagnosis             
   At/before birth   370   40.4   –0.1   NS   665   63.4   1.0   NS   2039   85.7   2.0   NS  
   After birth   524   57.1   0.2    354   33.8   1.0    272   11.4   2.6   
Age at first HTC visit, y             
   Younger than 1   255   27.8   –0.1   .02   480   45.8   0.9   NS   1554   65.4   1.7   <.001  
   1 to 2   130   14.2   –0.3    182   17.4   1.0    332   14.0   2.6   
   2+   501   54.6   0.4    339   32.4   1.2    387   16.3   3.2   
Insurance status             
   Insured   884   96.4   0.1   NS   1018   97.1   1.0   NS   2330   98.0   2.1   .03  
   Uninsured   33   3.6   0.1    30   2.9   1.2    48   2.0   3.8   
HTC use             
   Frequent   705   76.9   0.3   .01   924   88.2   1.2   <.01   2248   94.5   2.1   <.01  
   Infrequent   212   23.1   –0.3    124   11.8   0.1    130   5.5   3.4   
Inhibitor status             
   Yes   6   0.6   0   NS   25   2.4   1.5   NS   186   7.8   4.8   <.001  
   No   911   99.4   0.1    1023   97.6   1.0    2192   92.2   1.9   
Prophylaxis use             
   Yes   8   0.9   –0.5   NS   159   15.2   1.6   .04   1056   44.4   1.3   <.001  
   No   909   99.1   0.1    889   84.8   0.9    1322   55.6   2.8   
Body mass index             
   13.0 to 17.0   271   29.6   –0.6   <.001   328   31.3   –0.1   <.001   816   34.3   0.4   <.001  
   17.1 to 21.1   319   34.8   –0.2    352   33.6   0.6    742   31.2   2.1   
   21.2 to 42.0   309   33.7   0.9    345   32.9   2.4    760   32.0   4.1   
No. of bleeds, 6 mo             
   0   408   44.5   0.2   NS   261   24.9   0.6   NS   426   17.9   0.8   <.001  
   1 to 4   432   47.1   0.1    463   44.2   1.0    843   35.4   1.4   
   5+   77   8.4   0.1    322   30.7   1.4    1105   46.5   3.3   
Orthopedic procedure             
   Yes   10   1.1   0.6   NS   17   1.6   2.8   NS   103   4.3   5.6   <.001  
   No
 
907
 
98.9
 
0.1
 

 
1031
 
98.4
 
1.0
 

 
2275
 
95.7
 
2.0
 

 

Totals for characteristics do not all sum to 100% because of missing data.

NS indicates not significant.

*

P values of .05 or less indicate that average joint ROM limitation differs significantly across levels of the characteristic based on analysis of variance

Close Modal

or Create an Account

Close Modal
Close Modal